ECIK

ECIK (Enhanced Cytokine-Induced Killer cells) is an adoptive cell therapy developed by Shenzhen Hornetcorn Bio-technology Company. It involves the ex vivo expansion and activation of autologous immune cells, specifically a heterogeneous population of T lymphocytes that express both CD3 and CD56 surface markers. These "enhanced" CIK cells are designed to exhibit potent, non-MHC-restricted cytotoxic activity against a broad range of tumor cells. The therapy aims to harness the patient's own immune system to target and eliminate residual cancer cells, particularly in the context of solid tumors and hematological malignancies, often as an adjuvant treatment to prevent recurrence. The "enhanced" nature likely refers to optimized culture conditions or proprietary vector technologies used during the cell production process.

Other names

Enhanced CIK cellsEnhanced cytokine-induced killer cells